A Japanese conglomerate that is studying the anti-parasitic drug ivermectin has found that the medication had an antiviral effect on Omicron, according to joint non-clinical research.
Kowa Co. Ltd., a conglomerate with interests in trading, hospitality, and electronics, along with health and medical applications, issued a press release (pdf) on Jan. 31 stating that ivermectin has been found to be effective against Omicron in in vitro studies. The firm is also in the process of carrying out a Phase 3 clinical trial on the use of ivermectin to treat COVID-19…
